Plasma antioxidants and brain glucose metabolism in elderly subjects with cognitive complaints

PurposeThe role of oxidative stress is increasingly recognized in cognitive disorders of the elderly, notably Alzheimer’s disease (AD). In these subjects brain18F-FDG PET is regarded as a reliable biomarker of neurodegeneration. We hypothesized that oxidative stress could play a role in impairing brain glucose utilization in elderly subjects with increasing severity of cognitive disturbance.MethodsThe study group comprised 85 subjects with cognitive disturbance of increasing degrees of severity including 23 subjects with subjective cognitive impairment (SCI), 28 patients with mild cognitive impairment and 34 patients with mild AD. In all subjects brain FDG PET was performed and plasma activities of extracellular superoxide dismutase (eSOD), catalase and glutathione peroxidase were measured. Voxel-based analysis (SPM8) was used to compare FDG PET between groups and to evaluate correlations between plasma antioxidants and glucose metabolism in the whole group of subjects, correcting for age and Mini-Mental State Examination score.ResultsBrain glucose metabolism progressively decreased in the bilateral posterior temporoparietal and cingulate cortices across the three groups, from SCI to mild AD. eSOD activity was positively correlated with glucose metabolism in a large area of the left temporal lobe including the superior, middle and inferior temporal gyri and the fusiform gyrus.ConclusionThese results suggest a role of oxidative stress in the impairment of glucose utilization in the left temporal lobe structures in elderly patients with cognitive abnormalities, including AD and conditions predisposing to AD. Further studies exploring the oxidative stress–energy metabolism axis are considered worthwhile in larger groups of these patients in order to identify pivotal pathophysiological mechanisms and innovative therapeutic opportunities.

[1]  George Perry,et al.  Oxidative Stress and Neurodegeneration , 2005, Annals of the New York Academy of Sciences.

[2]  M. L’Abbé,et al.  Automated assay of superoxide dismutase in blood. , 1990, Methods in enzymology.

[3]  E. Klann,et al.  Mitochondrial superoxide: a key player in Alzheimer's disease , 2009, Aging.

[4]  Y. Sasaguri,et al.  Heparin-released extracellular superoxide dismutase is reduced in patients with coronary artery atherosclerosis. , 2006, Atherosclerosis.

[5]  M. Polidori,et al.  Bridging the pathophysiology of Alzheimer's disease with vascular pathology: the feed-back, the feed-forward, and oxidative stress. , 2012, Journal of Alzheimer's disease : JAD.

[6]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[7]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[8]  D. Butterfield,et al.  Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment , 2009, Journal of bioenergetics and biomembranes.

[9]  F. Faraci,et al.  Hypertrophy of Cerebral Arterioles in Mice Deficient in Expression of the Gene for CuZn Superoxide Dismutase , 2006, Stroke.

[10]  B. Ames.  Delaying the Mitochondrial Decay of Aging , 2004, Annals of the New York Academy of Sciences.

[11]  P. Mecocci,et al.  Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer’s disease , 2003, Neurobiology of Aging.

[12]  M. Lawton,et al.  Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living , 1969 .

[13]  J. C. de la Torre.  Alzheimer's disease: how does it start? , 2002, Journal of Alzheimer's disease : JAD.

[14]  G. Frisoni,et al.  Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  E. Cadenas,et al.  Oxidative stress: damage to intact cells and organs. , 1985, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[16]  Florian Auer,et al.  White matter hyperintensities predict amyloid increase in Alzheimer's disease , 2012, Neurobiology of Aging.

[17]  F. Kajiya,et al.  Role of Cu,Zn-SOD in the synthesis of endogenous vasodilator hydrogen peroxide during reactive hyperemia in mouse mesenteric microcirculation in vivo. , 2008, American journal of physiology. Heart and circulatory physiology.

[18]  Klaus P. Ebmeier,et al.  Global cognitive impairment should be taken into account in SPECT–neuropsychology correlations: the example of verbal memory in very mild Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  G. Frisoni,et al.  Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project , 2012, Neurobiology of Aging.

[20]  Manisha N. Patel,et al.  Mitochondria, oxidative stress, and temporal lobe epilepsy , 2010, Epilepsy Research.

[21]  Koen Van Laere,et al.  EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  L. Flohé,et al.  Assays of glutathione peroxidase. , 1984, Methods in enzymology.

[23]  Manuel Desco,et al.  Influence of the normalization template on the outcome of statistical parametric mapping of PET scans , 2003, NeuroImage.

[24]  Claire O'Tuathail,et al.  Assessment of older people , 2006 .

[25]  M. Mattson,et al.  Oxidative stress activates a positive feedback between the γ‐ and β‐secretase cleavages of the β‐amyloid precursor protein , 2007 .

[26]  Alin Ciobica,et al.  Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease , 2010, Neuroscience Letters.

[27]  A Hofman,et al.  Homocysteine and brain atrophy on MRI of non-demented elderly. , 2003, Brain : a journal of neurology.

[28]  P. Magistretti,et al.  Astrocyte–neuron metabolic relationships: for better and for worse , 2011, Trends in Neurosciences.

[29]  Marcella Laiacona,et al.  Tre test clinici di memoria verbale a lungo termine: Taratura su soggetti normali. , 1986 .

[30]  Christos Davatzikos,et al.  Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI , 2013, PloS one.

[31]  E. Zenteno,et al.  Amyloid-β25–35 impairs memory and increases NO in the temporal cortex of rats , 2009, Neuroscience Research.

[32]  S. Katz,et al.  Progress in development of the index of ADL. , 1970, The Gerontologist.

[33]  M. Baudry,et al.  Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline. , 2012, Journal of Alzheimer's Disease.

[34]  G. Perry,et al.  Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells , 2003, Journal of neuroscience research.

[35]  G. Perry,et al.  β‐Site APP cleaving enzyme up‐regulation induced by 4‐hydroxynonenal is mediated by stress‐activated protein kinases pathways , 2005, Journal of neurochemistry.

[36]  Petr Zach,et al.  Lateralization of 17Beta-Hydroxysteroid Dehydrogenase Type 10 in Hippocampi of Demented and Psychotic People , 2008, Dementia and Geriatric Cognitive Disorders.

[37]  C. Loeb,et al.  Diagnostic evaluation of degenerative and vascular dementia. , 1983, Stroke.

[38]  M. Ushio-Fukai,et al.  Superoxide dismutases: role in redox signaling, vascular function, and diseases. , 2011, Antioxidants & redox signaling.

[39]  H. Fukuyama,et al.  Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations , 2005, Neurology.

[40]  D. Butterfield,et al.  Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. , 2002, Journal of Alzheimer's disease : JAD.

[41]  D. Butterfield,et al.  Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. , 2013, Antioxidants & redox signaling.

[42]  M. L’Abbé,et al.  [21] Automated assay of superoxide dismutase in blood , 1990 .

[43]  T. Mariani,et al.  Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. , 2002, Free radical biology & medicine.

[44]  F. Faraci,et al.  Superoxide levels and function of cerebral blood vessels after inhibition of CuZn-SOD. , 2001, American journal of physiology. Heart and circulatory physiology.

[45]  E. Cadenas.  Mitochondrial free radical production and cell signaling. , 2004, Molecular aspects of medicine.

[46]  F. Faraci.  Protecting against vascular disease in brain. , 2011, American journal of physiology. Heart and circulatory physiology.

[47]  I W SIZER,et al.  A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. , 1952, The Journal of biological chemistry.

[48]  D. Gutsaeva,et al.  Involvement of Extracellular Superoxide Dismutase in Regulating Brain Blood Flow , 2009, Neuroscience and Behavioral Physiology.

[49]  Hong Yang,et al.  Reduction in extracellular superoxide dismutase activity in African-American patients with hypertension. , 2006, Free radical biology & medicine.

[50]  G. Perry,et al.  Chronological primacy of oxidative stress in Alzheimer disease , 2005, Neurobiology of Aging.

[51]  S. Marklund,et al.  10-fold increase in human plasma extracellular superoxide dismutase content caused by a mutation in heparin-binding domain. , 1994, The Journal of biological chemistry.

[52]  C Caltagirone,et al.  Regional grey matter loss and brain disconnection across Alzheimer disease evolution. , 2011, Current medicinal chemistry.

[53]  M. Mattson,et al.  Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. , 2008, Journal of neurochemistry.

[54]  M A Lovell,et al.  Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease , 2005, Journal of neurochemistry.

[55]  A. Federico,et al.  Mitochondria, oxidative stress and neurodegeneration , 2012, Journal of the Neurological Sciences.

[56]  Igor O. Korolev,et al.  Disruption of limbic white matter pathways in mild cognitive impairment and Alzheimer's disease: A DTI/FDG‐PET Study , 2012, Human brain mapping.

[57]  C. Behl.  Oxidative stress in Alzheimer's disease: implications for prevention and therapy. , 2005, Sub-cellular biochemistry.

[58]  P. Mecocci,et al.  Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[59]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[60]  George Perry,et al.  Activation of p38 Kinase Links Tau Phosphorylation, Oxidative Stress, and Cell Cycle‐Related Events in Alzheimer Disease , 2000 .

[61]  J. C. Torre.  Alzheimer's disease: how does it start? , 2002 .

[62]  P. Scheltens,et al.  A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT , 2001, Stroke.

[63]  C. Caltagirone,et al.  The Mental Deterioration Battery: Normative Data, Diagnostic Reliability and Qualitative Analyses of Cognitive Impairment , 1996 .

[64]  C. Jack,et al.  Fat-mass-related hormone, plasma leptin, predicts brain volumes in the elderly , 2013, Neuroreport.

[65]  Isidro Ferrer,et al.  Mitochondrial ATP‐Synthase in the Entorhinal Cortex Is a Target of Oxidative Stress at Stages I/II of Alzheimer's Disease Pathology , 2010, Brain pathology.